Pharmacology
All Targets
7-TM Receptors
Ion Channels
Nuclear Receptors
Enzyme-Linked Receptors
Transporters
Enzymes
Other Pharmacology
Cellular Processes
Angiogenesis
Apoptosis
Cell Cycle
Cell Metabolism
Cytoskeleton & Motor Proteins
ECM & Adhesion Molecules
Epigenetics
Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Home »
Pharmacology » Ion Channels » Ligand-gated Ion Channels » GABAA and GABAC Receptors » Miscellaneous GABA » trans-4-Hydroxycrotonic acid
trans-4-Hydroxycrotonic acidCat. No. 0538 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: trans-4-Hydroxy-2-butenoic acid |
Biological Activity
Binds to the γ-hydroxybutyric acid (GHB) receptor with higher affinity than GHB itself. May be an endogenous ligand.Certificate of Analysis / Safety Data Sheet
Certificate of Analysis: View current batch
Safety Data Sheet: View Safety Data Sheet
References
Vayer et al (1985) Natural occurrence of trans-gamma hydroxycrotonic acid in rat brain. Biochem.Pharmacol. 34 2401. PMID: 4015683.
Bourguignon et al (1988) Analogues of γ-hydroxybutyric acid. Synthesis and binding studies. J.Med.Chem. 31 893. PMID: 3361576.
Hechler et al (1993) Gamma hydroxybutyrate ligands posses antidopaminergic and neuroleptic-like activities. J.Pharmacol.Exp.Ther. 264 1406. PMID: 8095552.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: trans-4-Hydroxycrotonic acid, supplier, GHB, receptor, ligand, GABAB, Receptors, GABAA, GABAC
Quick Order
Find multiple products by catalog number
Tocris Events
Win a Kindle
5th Conference on Advances in Molecular Mechanisms Underlying Neurological Disorders
June 23 - 26, 2013
Bath, UK



